June 03, 2026
6 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Pooled phase 3 trials show reduced OSA severity with oral drug over 26 weeks
ORLANDO — Among adults with mild to severe obstructive sleep apnea, those receiving AD109, an oral combination drug, vs. placebo achieved lower disease severity at 26 weeks, according to pooled phase 3 trial results presented here.AD109 (Apnimed) is made up of 2.5 mg aroxybutynin, a novel antimuscarinic, and 75 mg atomoxetine, a selective norepinephrine reuptake inhibitor, according to a
1,792 words~8 min read
